Fexagratinib (AZD-4547; ADSK-091)

Alias: fexagratinib; AZD-4547; AZD 4547; AZD4547
Cat No.:V0616 Purity: ≥98%
AZD4547 (AZD-4547; AZD 4547) is a novel and orally bioavailable FGFR (fibroblast growth factor receptor) inhibitor with potential antineoplastic activity.
Fexagratinib (AZD-4547; ADSK-091) Chemical Structure CAS No.: 1035270-39-3
Product category: FGFR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
5mg
10mg
25mg
50mg
100mg
250mg
500mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

AZD4547 (AZD-4547; AZD 4547) is a novel and orally bioavailable FGFR (fibroblast growth factor receptor) inhibitor with potential antineoplastic activity. In cell-free assays, it inhibits FGFR1/2/3 with IC50s of 0.2 nM/2.5 nM/1.8 nM. However, its activity against other kinases, including FGFR4, VEGFR2(KDR), IGFR, CDK2, and p38, is minimal or weaker. Significant tumor-suppressive effects of AZD4547 are observed in mice with KMS11 tumors with a TGI of 53%.

Biological Activity I Assay Protocols (From Reference)
Targets
FGFR1 (IC50 = 0.2 nM); FGFR2 (IC50 = 2.5 nM); FGFR3 (IC50 = 1.8 nM); FGFR4 (IC50 = 165 nM)
ln Vitro
Fexagratinib also inhibits recombinant VEGFR2 (KDR) kinase activity with an IC50 of 24 nM. Fexagratinib exhibits a powerful inhibition of autophosphorylation of FGFR1, 2, and 3 tyrosine kinases (IC50 values of 12, 2, and 40 nM, respectively) in KG1a, Sum52-PE, MCF7, and KMS11 cell lines. However, it lessens the inhibition of FGFR4 cellular kinase activity (IC50=142 nM). Compared to cellular KDR and IGFR ligand-induced phosphorylation, significantly lower inhibitory activity is seen (IC50 values of 258 and 828 nM, respectively), indicating selectivity over cellular FGFR1 of about 20 and 70 times, respectively. Furthermore, FGFR phosphorylation and downstream signaling mediated by FRS2, PLCγ, and MAPK are potently inhibited by fexagratinib at the cellular level[1].
ln Vivo
Fexagratinib is administered chronically at various well-tolerated doses to female SCID mice with KMS11 tumors. The mice are treated in a randomized manner. Tumor growth inhibition is dose-dependent when administered orally with Fexagratinib. When compared to vehicle-treated controls, the administration of Fexagratinib at a dose of 3 mg/kg twice a day results in a statistically significant tumor growth inhibition of 53% (P0.0005 by one-tailed t test), whereas doses of 12.5 mg/kg once daily and 6.25 mg/kg twice a day result in complete tumor stasis (P0.0001). Fexagratinib at a dose of 12.5 mg/kg once daily in the KG1a model was found to be 65% effective in inhibiting tumor growth (P=0.002)[1].
Enzyme Assay
AZD4547 is tested with ATP concentrations at or slightly below the corresponding Km to see if it can inhibit the human recombinant kinase activities of FGFR1-3).
Cell Assay
For 72 hours, cell lines are incubated with AZD4547 at fixed concentrations. Cells are fixed with 70% ethanol and then incubated with a propidium iodide/RNase A labeling solution for fluorescence-activated cell sorting (FACS). CellQuest analysis software and an FACSCalibur instrument are used to evaluate cell-cycle profiles. Cells and media are carefully collected, centrifuged, and cell pellets are then washed in preparation for apoptotic analysis. Following that, the cells are prepared for propidium iodide uptake and FITC staining. A FACSCalibur device is then used to determine the percentage of cells that stain positively for Annexin V, and CellQuest analysis software is used to sort the cells into quadrants[1].
Animal Protocol
Mice: The mice used are Swiss-derived nude (nu/nu) and severe combined immunodeficient (SCID). Tumor xenografts are created by injecting 0.1 mL (1×106 for LoVo, 1×107 for HCT-15, and 1×107 for Calu-6) or 0.2 mL (2×107 for KMS11 and KG1a) of tumor cells mixed 1:1 with Matrigel into the left flank, with the exception of LoVo and HCT-15, which do not include Matrigel. Tumors that are larger than 0.2 cm3 are randomly assigned to treatment and control groups, and mice are given AZD4547 (1.5-50 mg/kg) orally once or twice a day. For the duration of the study, tumor condition, animal body weight, and tumor volume (measured using a caliper) are recorded twice a week. One computes the tumor volume.
References

[1]. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res, 2012, 72(8), 2045-2056.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C26H33N5O3
Molecular Weight
463.57
Exact Mass
463.26
Elemental Analysis
C, 67.36; H, 7.18; N, 15.11; O, 10.35
CAS #
1035270-39-3
Appearance
white solid powder
SMILES
C[C@@H]1CN(C[C@@H](N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC
InChi Key
VRQMAABPASPXMW-HDICACEKSA-N
InChi Code
InChI=1S/C26H33N5O3/c1-17-15-31(16-18(2)27-17)22-9-6-20(7-10-22)26(32)28-25-13-21(29-30-25)8-5-19-11-23(33-3)14-24(12-19)34-4/h6-7,9-14,17-18,27H,5,8,15-16H2,1-4H3,(H2,28,29,30,32)/t17-,18+
Chemical Name
N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-[(3S,5R)-3,5-dimethylpiperazin-1-yl]benzamide
Synonyms
fexagratinib; AZD-4547; AZD 4547; AZD4547
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~92 mg/mL (~198.5 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
4% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.1572 mL 10.7859 mL 21.5717 mL
5 mM 0.4314 mL 2.1572 mL 4.3143 mL
10 mM 0.2157 mL 1.0786 mL 2.1572 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02299999 Active
Recruiting
Drug: AZD2014
Drug: AZD4547
Metastatic Breast Cancer UNICANCER April 7, 2014 Phase 2
NCT02664935 Active
Recruiting
Drug: AZD4547
Drug: Vistusertib
Carcinoma, Squamous Cell
Adenocarcinoma
University of Birmingham May 2015 Phase 2
NCT02546661 Active
Recruiting
Drug: AZD4547
Drug: MEDI4736
Muscle Invasive Bladder Cancer AstraZeneca October 3, 2016 Phase 1
NCT05775874 Recruiting Drug: AZD4547
Drug: Tislelizumab
Urothelial Carcinoma Abbisko Therapeutics Co, Ltd September 30, 2022 Phase 2
NCT05086666 Recruiting Drug: AZD4547 Urothelial Carcinoma Abbisko Therapeutics Co, Ltd June 3, 2021 Phase 1
Phase 2
Biological Data
  • ZD4547

  • ZD4547
  • ZD4547

    AZD4547 exposure correlates with in vivo antitumor activity, pharmacodynamic modulation of phospho-FGFR, and reduced tumor cell proliferation. Cancer Res. 2012 Apr 15;72(8):2045-56.

Contact Us